Navigation Links
GlycoCheck Announces Partnership in the United States with Vascular Health Sciences

Maastricht, The Netherlands (PRWEB) January 16, 2013

GlycoCheck B.V., a leading provider of imaging and measurement software of the endothelial glycocalyx layer, today announced a reseller partnership with U.S.-based Vascular Health Sciences.

Vascular Health Sciences will exclusively distribute GlycoCheck Vascular Health Monitor (VHM) in the United States. GlycoCheck VHM is a complete imaging solution for screening patients’ perfused boundary layer inside the blood vessels. The new technology measures and monitors changes in the glycocalyx layer non-invasively, accurately and in real time.

“We are pleased that Vascular Health Sciences has made a commitment to offer our GlycoCheck VHM solution to their customers throughout the United States,” said GlycoCheck CEO Pieter Goedhart.

GlycoCheck recently debuted in U.S. markets when Vascular Health Sciences attended the Age Management Medicine and Holistic Primary Care Conferences when doctors offered very favorable reviews of both GlycoCheck and Vascular Health Sciences’ all-natural artery health supplement, Arterosil.

“GlycoCheck provides a unique and novel technology to assess artery health in real time,” said Vascular Health Sciences Co-Founder and CEO Bob Long. “The more trials we conduct, both in the clinical setting and in a non-controlled conference setting, the more positive evidence we observe that proves Arterosil and Arterosil HP work. We’re thrilled to offer the benefits of this new technology to Health Care Practitioners and their patients.”

About GlycoCheck
GlycoCheck is a leading provider of imaging solutions based on an innovative measurement system of the Glycocalyx layer. GlycoCheck solutions facilitate the accurate, reliable and non-invasive selection, detection & monitoring of patients in primary care, intensive care, cardiology and internal medicine. To learn more about GlycoCheck, visit

About Vascular Health Sciences
Founded in 2010, Vascular Health Sciences explores technologies, develops products and disseminates information to increase awareness and promote the proper care of the endothelial glycocalyx. Vascular Health Sciences is committed to increasing awareness of the glycocalyx and its role in vascular health, and to providing products supporting the care of this essential system. For more information, visit

About Arterosil
Arterosil, a product of Vascular Health Sciences, is an all-natural health supplement focused on vascular health. It’s the only health supplement scientifically proven to support and maintain the glycocalyx, – the micro-thin gel-like lining that protects the heart, veins and arteries.* It’s also scientifically proven to optimize capillary architecture and increase micro-circulatory functionality.* Arterosil is available at, where monthly auto-ship options are available with free shipping, as well as 30-, 90- and 365-day supplies. Learn more at, or find Arterosil on Facebook and follow Arterosil on Twitter.

*FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):